A synthetic GHRH analog studied for stimulating growth-hormone release. Exists in a short-acting 'no-DAC' form (modified GRF 1-29) and a long-acting 'DAC' form.
Mechanism under study
Binds the GHRH receptor on the pituitary to promote synthesis and pulsatile release of growth hormone; the DAC (Drug Affinity Complex) version binds albumin to extend half-life.
Research-reported dosing
Research references commonly cite ~100 mcg per dose for the no-DAC form, frequently paired with a ghrelin-receptor agonist; DAC references ~1–2 mg weekly. Not established in humans.
Based on a standard 5 mg vial: with 2 mL bacteriostatic water = 2,500 mcg/mL (2.5 mg/mL); 1 unit ≈ 25 mcg.
A 100 mcg dose ≈ 4 units (25 mcg per unit).
Open this mix in the calculator →Source research-grade CJC-1295 ↗Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
CJC-1295 comparisons
CJC-1295 FAQ
What is CJC-1295?
A synthetic GHRH analog studied for stimulating growth-hormone release. Exists in a short-acting 'no-DAC' form (modified GRF 1-29) and a long-acting 'DAC' form.
What is the half-life of CJC-1295?
No-DAC: ~30 minutes. DAC: reported to extend to several days, allowing less-frequent dosing.
What is the research-reported dosing for CJC-1295?
Research references commonly cite ~100 mcg per dose for the no-DAC form, frequently paired with a ghrelin-receptor agonist; DAC references ~1–2 mg weekly. Not established in humans.
How is CJC-1295 reconstituted?
Based on a standard 5 mg vial: with 2 mL bacteriostatic water = 2,500 mcg/mL (2.5 mg/mL); 1 unit ≈ 25 mcg.
Is CJC-1295 FDA-approved?
No — CJC-1295 is not FDA-approved and is sold for laboratory research use only.
References
Guides featuring CJC-1295
Related peptides
Ipamorelin
Ghrelin-receptor agonist (GH secretagogue)
A selective ghrelin-receptor agonist studied for stimulating growth-hormone release with comparatively little effect on cortisol or prolactin, making it a frequently referenced 'clean' secretagogue.
Sermorelin
Growth-hormone-releasing hormone (GHRH) analog
A GHRH (1-29) analog — the shortest fully active fragment of GHRH — historically used clinically as a diagnostic agent and studied for supporting endogenous growth-hormone output.
GHRP-2
Growth-hormone-releasing peptide (ghrelin-receptor agonist)
A potent growth-hormone-releasing peptide and ghrelin-receptor agonist studied for stimulating GH release; also investigated as a diagnostic test of pituitary GH reserve.